RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam® Apr 5, 2017
Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date Apr 5, 2017
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017 Mar 29, 2017
Naturally Splendid to Appear in the Canadian Cannabis Investor Magazine and on the U.S. Cannabis Investor Webcast Mar 29, 2017
RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems Mar 28, 2017
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities Mar 19, 2017
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office Mar 15, 2017
Naturally Splendid Packaging Line Commences Operations and Warrant Exercise Raises $445,425 Mar 14, 2017
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization Mar 8, 2017
DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD Mar 3, 2017
RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector Mar 1, 2017
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial Feb 24, 2017
